CrystalGenomics Inc (083790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CrystalGenomics Inc (083790) has a cash flow conversion efficiency ratio of -0.129x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-11.39 Billion ≈ $-7.72 Million USD) by net assets (₩87.96 Billion ≈ $59.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CrystalGenomics Inc market capitalisation for the company's overall valuation and market capitalisation.
CrystalGenomics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CrystalGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CrystalGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CrystalGenomics Inc ranked by their cash flow conversion efficiency. Explore CrystalGenomics Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C-Com Satellite Systems Inc.
V:CMI
|
-0.001x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
|
Geomega Resources Inc
V:GMA
|
-0.797x |
|
Etrend Hightech
TWO:3567
|
0.032x |
|
OSK Ventures International Bhd
KLSE:0053
|
-0.013x |
|
Apollo Power Ltd
TA:APLP
|
-0.074x |
|
Intergama
TA:INTR
|
0.054x |
|
SONOKONG Co. Ltd
KQ:066910
|
0.007x |
Annual Cash Flow Conversion Efficiency for CrystalGenomics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024. View current stock price of CrystalGenomics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩98.52 Billion ≈ $66.76 Million |
₩-25.85 Billion ≈ $-17.52 Million |
-0.262x | -17.63% |
| 2023-12-31 | ₩145.29 Billion ≈ $98.46 Million |
₩-32.41 Billion ≈ $-21.96 Million |
-0.223x | -72.08% |
| 2022-12-31 | ₩188.28 Billion ≈ $127.59 Million |
₩-24.40 Billion ≈ $-16.54 Million |
-0.130x | -135.12% |
| 2021-12-31 | ₩207.84 Billion ≈ $140.85 Million |
₩-11.46 Billion ≈ $-7.77 Million |
-0.055x | +27.74% |
| 2020-12-31 | ₩214.76 Billion ≈ $145.54 Million |
₩-16.38 Billion ≈ $-11.10 Million |
-0.076x | -59.32% |
| 2019-12-31 | ₩149.05 Billion ≈ $101.01 Million |
₩-7.14 Billion ≈ $-4.84 Million |
-0.048x | -632.04% |
| 2018-12-31 | ₩184.47 Billion ≈ $125.01 Million |
₩-1.21 Billion ≈ $-817.78K |
-0.007x | -136.69% |
| 2017-12-31 | ₩91.59 Billion ≈ $62.07 Million |
₩1.63 Billion ≈ $1.11 Million |
0.018x | +117.86% |
| 2016-12-31 | ₩83.16 Billion ≈ $56.36 Million |
₩-8.30 Billion ≈ $-5.63 Million |
-0.100x | -51.96% |
| 2015-12-31 | ₩71.94 Billion ≈ $48.75 Million |
₩-4.73 Billion ≈ $-3.20 Million |
-0.066x | +3.72% |
| 2014-12-31 | ₩55.03 Billion ≈ $37.29 Million |
₩-3.75 Billion ≈ $-2.54 Million |
-0.068x | -- |
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more